Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy

• Published in: Drug design, development and therapy Vol. 13; pp. 3635 - 3646
• Main Authors: Bova, Maria, Valerieva, Anna, Wu, Maddalena Alessandra, Senter, Riccardo, Perego, Francesca
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-10-2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Angioedema; Angioedemas, Hereditary - drug therapy; Angioedemas, Hereditary - physiopathology; Angioneurotic edema; Animals; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Bradykinin; Bradykinin - antagonists & inhibitors; Bradykinin - metabolism; C1-inhibitor hereditary angioedema; Care and treatment; Clinical trials; Disease prevention; Drug Development - methods; Drug dosages; Ecallantide; Edema; Humans; Icatibant; Lanadelumab; long-term prophylaxis; Monoclonal antibodies; monoclonal antibody; Mutation; Preventive medicine; Prophylaxis; Quality of Life; rare disease; Rare diseases; Review; Side effects; Vasodilation; United States > US; Italy; San Francisco California; C1-inhibitor hereditary angioedema; long-term prophylaxis; rare disease; monoclonal antibody; lanadelumab
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/dddt.s192475

Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal antibody, lanadelumab, directly addressed to the blockage of bradykinin, the principal mediator of vasodilation during angioedema attacks. It is indicated for the prophylactic treatment, it is easy to administer, highly effective and with known limited side effects. The current review summarizes the development of the drug, its clinical background and its perspectives.